methyl 4'-cyano-3,3'-difluoro-1,1'-biphenyl-2-carboxylate | 1026635-99-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4'-cyano-3,3'-difluoro-1,1'-biphenyl-2-carboxylate
• 英文别名: methyl 4′-cyano-3,3′-difluorobiphenyl-2-carboxylate；Methyl 2-(4-cyano-3-fluorophenyl)-6-fluorobenzoate
• CAS: 1026635-99-3
• 化学式: C₁₅H₉F₂NO₂
• 分子量: 273.239
• InChiKey: UNJJZCPJIIQSJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 4'-cyano-3,3'-difluoro-1,1'-biphenyl-2-carboxylate 在 镍 sodium hydroxide 、 TEA 、 氨 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 6-({[3,3'-difluoro-2'-(methoxycarbonyl)biphenyl-4-yl]methyl}amino)nicotinic acid
  参考文献：
  名称：

  5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists

  摘要：

  A series of 2,3-diaminopyridine bradykinin B-1 antagonists was modified to mitigate the potential for bioactivation. Removal of the 3-amino group and incorporation of basic 5-piperazinyl carboxamides at the pyridine 5-position provided compounds with high affinity for the human B-1 receptor. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.112
• 作为产物：
  描述：

  2-氟-6-碘苯甲酸 在 锌 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 反应 7.5h， 生成 methyl 4'-cyano-3,3'-difluoro-1,1'-biphenyl-2-carboxylate
  参考文献：
  名称：

  Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B₁ Receptor Antagonists

  摘要：

  A series of biphenylaminocyclopropane carboxamide based bradykinin B-1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B-1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

  DOI：

  10.1021/jm061094b

文献信息

• NHC-Cu(I)-Catalyzed Friedländer-Type Annulation of Fluorinated <i>o</i>-Aminophenones with Alkynes on Water: Competitive Base-Catalyzed Dibenzo[<i>b</i>,<i>f</i>][1,5]diazocine Formation
  作者：Paweł Czerwiński、Michał Michalak

  DOI：10.1021/acs.joc.7b01235

  日期：2017.8.4

  good yields. Further investigations proved that o-FMKs could be efficiently transformed into a rare class of heterocyclic compounds—dibenzo[b,f][1,5]diazocines—by a base-catalyzed condensation, also on water. The developed method was applied for gram-scale synthesis of a fluorinated analogue of G protein-coupled receptor antagonist (GPR91).

  4- trifluoromethylquinolines和naphthydrines（以及它们的二氟和全氟类似物）一种高效，易于扩展的合成作为串联直接催化炔基/脱水缩合的结果Ô -aminofluoromethylketones（ø -FMKs），首次催化报道了NHC-铜（I）在水上的配合物。在反应条件下可耐受各种末端炔烃，包括β-内酰胺，甾体和糖衍生的炔烃，从而可得到所需的喹啉和萘酚，并具有良好的收率。进一步的研究证明，o -FMKs可以有效地转化为稀有的杂环化合物，即二苯并[ b，f] [1,5]重氮电影—通过碱催化的缩合反应，也可以在水上进行。所开发的方法被用于克规模的G蛋白偶联受体拮抗剂（GPR91）的氟化类似物的合成。
• SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS
  申请人：Jerini AG

  公开号：EP2396301A2

  公开（公告）日：2011-12-21
• [EN] SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS<br/>[FR] PETITES MOLÉCULES ANTAGONISTES DU RÉCEPTEUR B1 DE LA BRADYKININE
  申请人：JERINI AG

  公开号：WO2010091876A2

  公开（公告）日：2010-08-19

  The present invention is related to a compound of the formula (I): or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein A is formula (II) (III) (IV), X is Ch or N; R1, R2, R3, R4, R6, R7, and R8 are each and independently of each other selected from hydrogen atom, halogen atom, hydroxy, cyano, amino, alkyl, or optionally substituted heteroalkyl; R5 is a halogen atom, hydroxy, cyano, amino, an alkyl, an optionally substituted heteroalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted alkylcycloalkyl, an optionally substituted heteroalkylcycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl; R9 is a hydrogen atom, an alkyl, or a heteroalkyl; R10 is a hydrogen atom, an alkyl, an optionally substituted heteroalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl; R11 is an alkyl, an optionally substituted heteroalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted alkylcycloalkyl, an optionally substituted heteroalkylcycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl; R12 is a hydrogen atom, an alkyl, an optionally substituted heteroalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl; B is O or N; Z1 and Z2 are each and independently of each other selected from C or N, and Z3 and Z4 are each and independently of each other selected from C, S, O or N; R13 is an alkyl, an optionally substituted heteroalkyl, an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted alkylcycloalkyl, an optionally substituted heteroalkylcycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl; R14 and R15, if present, are (i) each and independently of each other selected from hydrogen atom, halogen atom, CN, hydroxy, =O, alkyl, C3-C6-cycloalkyl, heteroalkyl or alkoxy; or (ii) joined together to form a carbocyclic or heterocyclic 5- or 6-membered ring, which is substituted with 0 to 4 substituents selected from the group comprising R16, R17, R18 and R19, and is saturated, unsaturated, or aromatic, and, if heterocyclic, contains one or more heteroatom(s) each and independently selected from N, O and S; and R16, R17, R18 and R19 are individually and independently selected from hydrogen atom, halogen atom, hydroxy, cyano, amino, alkyl, and optionally substituted heteroalkyl.
• Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B₁ Receptor Antagonists
  作者：Scott D. Kuduk、Christina N. Di Marco、Ronald K. Chang、Michael R. Wood、Kathy M. Schirripa、June J. Kim、Jenny M. C. Wai、Robert M. DiPardo、Kathy L. Murphy、Richard W. Ransom、C. Meacham Harrell、Duane R. Reiss、Marie A. Holahan、Jacquelynn Cook、J. Fred Hess、Nova Sain、Mark O. Urban、Cuyue Tang、Thomayant Prueksaritanont、Douglas J. Pettibone、Mark G. Bock

  DOI：10.1021/jm061094b

  日期：2007.1.1

  A series of biphenylaminocyclopropane carboxamide based bradykinin B-1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B-1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.
• 5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists
  作者：Scott D. Kuduk、Christina Ng Di Marco、Ronald K. Chang、Michael R. Wood、June J. Kim、Kathy M. Schirripa、Kathy L. Murphy、Richard W. Ransom、Cuyue Tang、Maricel Torrent、Sookhee Ha、Thomayant Prueksaritanont、Douglas J. Pettibone、Mark G. Bock

  DOI：10.1016/j.bmcl.2006.01.112

  日期：2006.5

  A series of 2,3-diaminopyridine bradykinin B-1 antagonists was modified to mitigate the potential for bioactivation. Removal of the 3-amino group and incorporation of basic 5-piperazinyl carboxamides at the pyridine 5-position provided compounds with high affinity for the human B-1 receptor. (C) 2006 Elsevier Ltd. All rights reserved.